Liraglutide 3.0 mg daily investigated for improving 9-month weight loss in bariatric surgery low-responders.

Obesity remains a significant global health challenge, with bariatric surgery being the most effective intervention for substantial and sustained weight loss. However, a subset of patients experiences suboptimal weight loss or weight regain, often termed "low responders." These individuals represent a critical unmet need, as their initial surgical investment does not yield the anticipated health benefits, leading to potential frustration and continued metabolic complications. Current post-surgical management often lacks targeted pharmacological strategies for these specific low-responder populations. Liraglutide, a GLP-1 receptor agonist, has demonstrated efficacy in weight management, offering a potential adjunct therapy to improve outcomes in these challenging cases by enhancing satiety and reducing appetite.

This study aims to evaluate the effect of Liraglutide 3.0 mg daily on weight loss outcomes. The intervention involves administering Liraglutide 3.0 mg daily to patients identified as low responders three months after undergoing bariatric surgery. The primary endpoint is the assessment of 9-month weight loss from the point of Liraglutide initiation. The study design focuses on a specific patient cohort: individuals who have not achieved adequate weight loss response following their initial bariatric procedure.